Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Veracyte, inc. save search
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Published: 2024-04-22 (Crawled : 17:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 1.03%
H: 2.65%
C: 1.02%
active test cancer for study
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Published: 2024-02-27 (Crawled : 00:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 0.68%
H: 0.34%
C: -0.42%
guidelines test cancer molecular
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
Published: 2023-12-01 (Crawled : 23:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -0.51%
H: 4.28%
C: 4.2%
genomic cancer show
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
Published: 2023-11-29 (Crawled : 15:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 1.9%
H: 2.74%
C: -2.06%
lung test cancer risk
Cancer Biopsy Market Share is Expected to Reach USD 92.09 Billion By 2032, Growing at 14.8% CAGR: Polaris Market Research
Published: 2023-11-27 (Crawled : 15:30) - prnewswire.com
TMO | News | $574.59 4.78% 3.34% 2.2M
|
Health Technology
|
| O: 0.1%
H: 0.86%
C: 0.19%
QGEN | $41.89 1.63% 0.0% 760K
|
Health Technology
|
| O: 0.37%
H: 0.46%
C: -1.1%
PHG | News | $21.01 1.94% 0.0% 2M
|
Health Technology
|
| O: 0.09%
H: 0.7%
C: 0.47%
DHR | $253.11 7.21% -0.06% 5.9M
|
Health Technology
|
| O: -0.41%
H: 0.67%
C: -0.23%
BIO | $285.28 1.84% 0.0% 250K
|
Health Technology
|
| O: -0.71%
H: 0.05%
C: -0.6%
BDX | $234.36 0.21% 0.29% 570K
|
Health Technology
|
| O: -0.1%
H: 0.73%
C: 0.08%
ABT | News | $107.59 0.49% 0.33% 3.1M
|
Health Technology
|
| O: -0.2%
H: 0.85%
C: 0.11%
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -0.95%
H: 2.93%
C: 1.66%
QGEN | $41.89 1.63% 0.0% 760K
|
Health Technology
|
| O: 0.37%
H: 0.46%
C: -1.1%
NEO | $14.16 5.51% 5.29% 850K
|
Health Services
|
| O: -0.16%
H: 0.21%
C: -1.14%
MYGN | $18.6 0.6% 0.56% 510K
|
Health Technology
|
| O: -0.55%
H: 1.45%
C: 0.5%
ILMN | $124.46 3.5% 3.34% 1.1M
|
Health Technology
|
| O: -1.5%
H: 0.97%
C: -2.28%
HOLX | $77.19 1.27% 1.26% 1.6M
|
Health Technology
|
| O: -0.42%
H: 0.43%
C: 0.13%
expected reach cancer research growing market
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
Published: 2023-09-28 (Crawled : 23:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 0.39%
H: 2.27%
C: -0.17%
cancer thyroid meeting molecular
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
Published: 2023-09-06 (Crawled : 13:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 0.23%
H: 0.8%
C: -0.88%
companies cancer collaboration
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
Published: 2023-08-22 (Crawled : 14:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 3.25%
H: 0.22%
C: -2.62%
cancer treatment response potential
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
Published: 2023-08-01 (Crawled : 13:20) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: -0.81%
genomic cancer treatment study
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
Published: 2023-06-20 (Crawled : 22:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 0.0%
H: 1.3%
C: 0.61%
cancer thyroid molecular
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Published: 2023-05-31 (Crawled : 16:00) - biospace.com/
INAB | $1.04 4.01% 3.39% 280K
|
|
| O: 0.35%
H: 6.57%
C: 5.19%
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -0.43%
H: 3.05%
C: 1.21%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.81%
JAZZ | $109.67 0.77% 0.78% 380K
|
Health Technology
|
| O: -0.09%
H: 2.57%
C: 1.13%
GERN | $3.5 -6.17% -6.72% 8.3M
|
Health Technology
|
| O: 0.6%
H: 2.1%
C: -2.1%
asco cancer meeting set
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
Published: 2023-05-24 (Crawled : 17:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -1.42%
H: 1.83%
C: 1.21%
lung disease genomic cancer
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
Published: 2023-05-12 (Crawled : 12:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: -0.76%
test breast cancer treatment show
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
Published: 2023-05-04 (Crawled : 15:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -1.91%
H: 7.37%
C: 5.45%
cancer risk thyroid
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
Published: 2023-05-03 (Crawled : 23:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 1.67%
H: 4.41%
C: 0.99%
cancer treatment
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
Published: 2023-04-12 (Crawled : 14:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 3.09%
H: 1.18%
C: -3.58%
cancer meeting
United States Prostate Cancer Testing Market Report 2022: A $544 Million Market by 2030 - Increasing Number of Prostate Cancer Screening and Testing
Published: 2023-02-28 (Crawled : 11:00) - prnewswire.com
A | $139.2 3.95% 0.5% 1.7M
|
Health Technology
|
| O: -0.3%
H: 1.15%
C: 0.16%
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -0.33%
H: 4.68%
C: 1.95%
OPK | $1.25 1.63% 1.2% 1.7M
|
Health Technology
|
| O: 0.88%
H: 1.75%
C: 0.0%
MYGN | $18.6 0.6% 0.56% 510K
|
Health Technology
|
| O: -0.59%
H: 4.95%
C: 1.83%
EXAS | $63.53 1.8% 1.79% 1.3M
|
Health Technology
|
| O: -0.38%
H: 4.78%
C: 3.92%
ABCM | News | $23.99 0.0% 7.4M
|
Health Technology
|
| O: -0.7%
H: 1.61%
C: 1.05%
report cancer market
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
Published: 2023-02-15 (Crawled : 16:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -0.04%
H: 4.35%
C: 4.08%
genomic cancer prostate cancer
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
Published: 2023-02-13 (Crawled : 00:00) - biospace.com/
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: 0.12%
H: 4.06%
C: 3.08%
treatment asco cancer prostate cancer
Global Prostate Cancer Testing Market Research Report 2022: The Focus of Business Leaders is Establishing a Deep Understanding to Address the Unmet Needs in Clinical Research
Published: 2023-02-08 (Crawled : 17:00) - prnewswire.com
A | $139.2 3.95% 0.5% 1.7M
|
Health Technology
|
| O: -0.56%
H: 1.0%
C: 0.51%
VCYT | News | $19.83 -0.1% -0.15% 560K
|
Health Technology
|
| O: -1.3%
H: 2.97%
C: 0.08%
OPK | $1.25 1.63% 1.2% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.19%
MYGN | $18.6 0.6% 0.56% 510K
|
Health Technology
|
| O: -0.82%
H: 3.81%
C: -2.93%
EXAS | $63.53 1.8% 1.79% 1.3M
|
Health Technology
|
| O: -0.53%
H: 2.18%
C: -0.57%
ABCM | News | $23.99 0.0% 7.4M
|
Health Technology
|
| O: -0.64%
H: 2.25%
C: -2.76%
research global report cancer market prostate cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.